- Home
- SIGI vs NUVL Comparison
SIGI vs NUVL Comparison
Compare SIGI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGI
- NUVL
- Stock Information
- Founded
- SIGI 1926
- NUVL 2017
- Country
- SIGI United States
- NUVL United States
- Employees
- SIGI N/A
- NUVL N/A
- Industry
- SIGI Property-Casualty Insurers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- SIGI Finance
- NUVL Health Care
- Exchange
- SIGI Nasdaq
- NUVL Nasdaq
- Market Cap
- SIGI 5.1B
- NUVL 5.6B
- IPO Year
- SIGI N/A
- NUVL 2021
- Fundamental
- Price
- SIGI $87.09
- NUVL $65.15
- Analyst Decision
- SIGI Hold
- NUVL Strong Buy
- Analyst Count
- SIGI 9
- NUVL 10
- Target Price
- SIGI $98.71
- NUVL $113.10
- AVG Volume (30 Days)
- SIGI 373.3K
- NUVL 588.4K
- Earning Date
- SIGI 04-30-2025
- NUVL 05-08-2025
- Dividend Yield
- SIGI 1.64%
- NUVL N/A
- EPS Growth
- SIGI N/A
- NUVL N/A
- EPS
- SIGI 3.23
- NUVL N/A
- Revenue
- SIGI $4,861,664,000.00
- NUVL N/A
- Revenue This Year
- SIGI $6.22
- NUVL N/A
- Revenue Next Year
- SIGI $6.68
- NUVL N/A
- P/E Ratio
- SIGI $28.66
- NUVL N/A
- Revenue Growth
- SIGI 14.88
- NUVL N/A
- 52 Week Low
- SIGI $78.13
- NUVL $61.80
- 52 Week High
- SIGI $106.01
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- SIGI 55.45
- NUVL 32.14
- Support Level
- SIGI $90.02
- NUVL $67.47
- Resistance Level
- SIGI $93.19
- NUVL $77.93
- Average True Range (ATR)
- SIGI 1.96
- NUVL 3.14
- MACD
- SIGI 0.18
- NUVL -0.71
- Stochastic Oscillator
- SIGI 51.03
- NUVL 7.83
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. Since 1977, Selective has focused its sales efforts on small businesses, offering commercial products that include workers' compensation, general liability, property, and auto insurance. Selective also has a small personal insurance segment (under 20% of total premiums), selling auto and homeowner's coverage.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.